Invanz and Progressive multifocal leukoencephalopathy - a phase IV clinical study of FDA data

Summary:

Progressive multifocal leukoencephalopathy is reported as a side effect among people who take Invanz (ertapenem sodium), especially for people who are female, 50-59 old, also take Reglan, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Progressive multifocal leukoencephalopathy when taking Invanz. It is created by eHealthMe based on reports of 3,924 people who have side effects when taking Invanz from the FDA, and is updated regularly.

What is Invanz?

Invanz has active ingredients of ertapenem sodium. It is often used in urinary tract infection. eHealthMe is studying from 3,961 Invanz users. Check the latest studies of Invanz.

What is Progressive multifocal leukoencephalopathy?

Progressive multifocal leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells) is found to be associated with 592 drugs and 921 conditions by eHealthMe. Check the latest studies of Progressive multifocal leukoencephalopathy.

On Jul, 27, 2026

3,924 people reported to have side effects when taking Invanz.
Among them, 23 people (0.59%) have Progressive multifocal leukoencephalopathy.

Could Invanz cause Progressive multifocal leukoencephalopathy?

Among these 23 people:

What is the gender of people who have Progressive multifocal leukoencephalopathy when taking Invanz? *

female: 95.65 %
male: 4.35 %

What is the age of people who have Progressive multifocal leukoencephalopathy when taking Invanz? *

What are other drugs people take besides Invanz? *

What are other side effects people have besides Progressive multifocal leukoencephalopathy? *

Sinusitis (inflammation of sinus): 6 people, 26.09%
Staphylococcal Infection (an infection with staphylococcus bacteria): 6 people, 26.09%
Fever: 5 people, 21.74%
Hypovolaemia (a decreased volume of circulating blood in the body): 4 people, 17.39%
Depression: 4 people, 17.39%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 4 people, 17.39%
Swallowing Difficulty: 4 people, 17.39%
Oropharyngeal Cancer Stage Unspecified: 4 people, 17.39%
Pharyngeal Inflammation: 3 people, 13.04%
Hypophagia (reduced food intake): 3 people, 13.04%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 23 people, 100.00%
Tonsil Cancer: 22 people, 95.65%
Thrombosis (formation of a blood clot inside a blood vessel): 1 person, 4.35%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Invanz and have Progressive multifocal leukoencephalopathy?

- Check whether Progressive multifocal leukoencephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Invanz:

Invanz (3,961 reports)

Progressive multifocal leukoencephalopathy treatments and more:

Progressive multifocal leukoencephalopathy (13,731 reports)

How severe was Progressive multifocal leukoencephalopathy and when was it recovered:

Progressive multifocal leukoencephalopathy in Invanz

Expand to all the drugs that have ingredients of ertapenem sodium:

Progressive multifocal leukoencephalopathy and drugs with ingredients of ertapenem sodium (24 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Invanz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Progressive multifocal leukoencephalopathy:

Progressive multifocal leukoencephalopathy (592 drugs)

Browse all the conditions that are associated with Progressive multifocal leukoencephalopathy:

Progressive multifocal leukoencephalopathy (921 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ertapenem sodium (the active ingredients of Invanz) and Invanz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.